Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at William Blair issued their Q4 2017 earnings estimates for Hologic in a note issued to investors on Tuesday. William Blair analyst B. Weinstein anticipates that the medical equipment provider will post earnings of $0.49 per share for the quarter. William Blair also issued estimates for Hologic’s Q1 2018 earnings at $0.52 EPS, Q2 2018 earnings at $0.52 EPS, Q3 2018 earnings at $0.54 EPS and Q4 2018 earnings at $0.53 EPS.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the business posted $0.51 EPS. ILLEGAL ACTIVITY NOTICE: “William Blair Weighs in on Hologic, Inc.’s Q4 2017 Earnings (HOLX)” was reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2017/09/13/william-blair-weighs-in-on-hologic-inc-s-q4-2017-earnings-holx.html.
A number of other research firms also recently commented on HOLX. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Royal Bank Of Canada dropped their price objective on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Thursday, August 3rd. Deutsche Bank AG dropped their price objective on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 price objective on shares of Hologic in a report on Friday, July 14th. Finally, Barclays PLC dropped their price objective on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $48.64.
Hologic (HOLX) opened at 38.19 on Wednesday. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80. The company has a 50-day moving average price of $39.72 and a 200-day moving average price of $42.69. The stock has a market cap of $10.71 billion, a PE ratio of 14.22 and a beta of 0.92.
In other Hologic news, Director Elaine Ullian sold 8,849 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the sale, the director now directly owns 23,810 shares in the company, valued at $1,078,116.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. Insiders sold 27,594 shares of company stock valued at $1,168,871 over the last 90 days. Corporate insiders own 0.79% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Hall Laurie J Trustee increased its holdings in shares of Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares in the last quarter. Commonwealth Bank of Australia increased its holdings in shares of Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares in the last quarter. TrimTabs Asset Management LLC increased its holdings in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after acquiring an additional 1,408 shares in the last quarter. National Asset Management Inc. bought a new stake in shares of Hologic in the second quarter worth about $203,000. Finally, Miles Capital Inc. bought a new stake in shares of Hologic in the first quarter worth about $206,000. Institutional investors own 96.39% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.